Identification of a biological signature for schizophrenia in serum

E. Schwarz, P. C. Guest, H. Rahmoune, L. W. Harris, L. Wang, F. M. Leweke, M. Rothermundt, B. Bogerts, D. Koethe, L. Kranaster, P. Ohrmann, T. Suslow, G. McAllister, M. Spain, A. Barnes, N. J M Van Beveren, S. Baron-Cohen, J. Steiner, F. E. Torrey, Robert H Yolken & 1 others S. Bahn

Research output: Contribution to journalArticle

Abstract

Biomarkers are now used in many areas of medicine but are still lacking for psychiatric conditions such as schizophrenia (SCZ). We have used a multiplex molecular profiling approach to measure serum concentrations of 181 proteins and small molecules in 250 first and recent onset SCZ, 35 major depressive disorder (MDD), 32 euthymic bipolar disorder (BPD), 45 Asperger syndrome and 280 control subjects. Preliminary analysis resulted in identification of a signature comprised of 34 analytes in a cohort of closely matched SCZ (n = 71) and control (n = 59) subjects. Partial least squares discriminant analysis using this signature gave a separation of 60-75% of SCZ subjects from controls across five independent cohorts. The same analysis also gave a separation of ∼50% of MDD patients and 10-20% of BPD and Asperger syndrome subjects from controls. These results demonstrate for the first time that a biological signature for SCZ can be identified in blood serum. This study lays the groundwork for development of a diagnostic test that can be used as an aid for distinguishing SCZ subjects from healthy controls and from those affected by related psychiatric illnesses with overlapping symptoms.

Original languageEnglish (US)
Pages (from-to)494-502
Number of pages9
JournalMolecular Psychiatry
Volume17
Issue number5
DOIs
StatePublished - May 2012
Externally publishedYes

Fingerprint

Schizophrenia
Serum
Asperger Syndrome
Major Depressive Disorder
Bipolar Disorder
Psychiatry
Discriminant Analysis
Least-Squares Analysis
Routine Diagnostic Tests
Healthy Volunteers
Biomarkers
Medicine
Proteins

Keywords

  • biomarkers
  • bipolar disorder
  • diagnosis
  • major depressive disorder
  • multipleximmunoassay
  • schizophrenia

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Schwarz, E., Guest, P. C., Rahmoune, H., Harris, L. W., Wang, L., Leweke, F. M., ... Bahn, S. (2012). Identification of a biological signature for schizophrenia in serum. Molecular Psychiatry, 17(5), 494-502. https://doi.org/10.1038/mp.2011.42

Identification of a biological signature for schizophrenia in serum. / Schwarz, E.; Guest, P. C.; Rahmoune, H.; Harris, L. W.; Wang, L.; Leweke, F. M.; Rothermundt, M.; Bogerts, B.; Koethe, D.; Kranaster, L.; Ohrmann, P.; Suslow, T.; McAllister, G.; Spain, M.; Barnes, A.; Van Beveren, N. J M; Baron-Cohen, S.; Steiner, J.; Torrey, F. E.; Yolken, Robert H; Bahn, S.

In: Molecular Psychiatry, Vol. 17, No. 5, 05.2012, p. 494-502.

Research output: Contribution to journalArticle

Schwarz, E, Guest, PC, Rahmoune, H, Harris, LW, Wang, L, Leweke, FM, Rothermundt, M, Bogerts, B, Koethe, D, Kranaster, L, Ohrmann, P, Suslow, T, McAllister, G, Spain, M, Barnes, A, Van Beveren, NJM, Baron-Cohen, S, Steiner, J, Torrey, FE, Yolken, RH & Bahn, S 2012, 'Identification of a biological signature for schizophrenia in serum', Molecular Psychiatry, vol. 17, no. 5, pp. 494-502. https://doi.org/10.1038/mp.2011.42
Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM et al. Identification of a biological signature for schizophrenia in serum. Molecular Psychiatry. 2012 May;17(5):494-502. https://doi.org/10.1038/mp.2011.42
Schwarz, E. ; Guest, P. C. ; Rahmoune, H. ; Harris, L. W. ; Wang, L. ; Leweke, F. M. ; Rothermundt, M. ; Bogerts, B. ; Koethe, D. ; Kranaster, L. ; Ohrmann, P. ; Suslow, T. ; McAllister, G. ; Spain, M. ; Barnes, A. ; Van Beveren, N. J M ; Baron-Cohen, S. ; Steiner, J. ; Torrey, F. E. ; Yolken, Robert H ; Bahn, S. / Identification of a biological signature for schizophrenia in serum. In: Molecular Psychiatry. 2012 ; Vol. 17, No. 5. pp. 494-502.
@article{d8d2d141ab2c4863aaf035bae19eacbe,
title = "Identification of a biological signature for schizophrenia in serum",
abstract = "Biomarkers are now used in many areas of medicine but are still lacking for psychiatric conditions such as schizophrenia (SCZ). We have used a multiplex molecular profiling approach to measure serum concentrations of 181 proteins and small molecules in 250 first and recent onset SCZ, 35 major depressive disorder (MDD), 32 euthymic bipolar disorder (BPD), 45 Asperger syndrome and 280 control subjects. Preliminary analysis resulted in identification of a signature comprised of 34 analytes in a cohort of closely matched SCZ (n = 71) and control (n = 59) subjects. Partial least squares discriminant analysis using this signature gave a separation of 60-75{\%} of SCZ subjects from controls across five independent cohorts. The same analysis also gave a separation of ∼50{\%} of MDD patients and 10-20{\%} of BPD and Asperger syndrome subjects from controls. These results demonstrate for the first time that a biological signature for SCZ can be identified in blood serum. This study lays the groundwork for development of a diagnostic test that can be used as an aid for distinguishing SCZ subjects from healthy controls and from those affected by related psychiatric illnesses with overlapping symptoms.",
keywords = "biomarkers, bipolar disorder, diagnosis, major depressive disorder, multipleximmunoassay, schizophrenia",
author = "E. Schwarz and Guest, {P. C.} and H. Rahmoune and Harris, {L. W.} and L. Wang and Leweke, {F. M.} and M. Rothermundt and B. Bogerts and D. Koethe and L. Kranaster and P. Ohrmann and T. Suslow and G. McAllister and M. Spain and A. Barnes and {Van Beveren}, {N. J M} and S. Baron-Cohen and J. Steiner and Torrey, {F. E.} and Yolken, {Robert H} and S. Bahn",
year = "2012",
month = "5",
doi = "10.1038/mp.2011.42",
language = "English (US)",
volume = "17",
pages = "494--502",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Identification of a biological signature for schizophrenia in serum

AU - Schwarz, E.

AU - Guest, P. C.

AU - Rahmoune, H.

AU - Harris, L. W.

AU - Wang, L.

AU - Leweke, F. M.

AU - Rothermundt, M.

AU - Bogerts, B.

AU - Koethe, D.

AU - Kranaster, L.

AU - Ohrmann, P.

AU - Suslow, T.

AU - McAllister, G.

AU - Spain, M.

AU - Barnes, A.

AU - Van Beveren, N. J M

AU - Baron-Cohen, S.

AU - Steiner, J.

AU - Torrey, F. E.

AU - Yolken, Robert H

AU - Bahn, S.

PY - 2012/5

Y1 - 2012/5

N2 - Biomarkers are now used in many areas of medicine but are still lacking for psychiatric conditions such as schizophrenia (SCZ). We have used a multiplex molecular profiling approach to measure serum concentrations of 181 proteins and small molecules in 250 first and recent onset SCZ, 35 major depressive disorder (MDD), 32 euthymic bipolar disorder (BPD), 45 Asperger syndrome and 280 control subjects. Preliminary analysis resulted in identification of a signature comprised of 34 analytes in a cohort of closely matched SCZ (n = 71) and control (n = 59) subjects. Partial least squares discriminant analysis using this signature gave a separation of 60-75% of SCZ subjects from controls across five independent cohorts. The same analysis also gave a separation of ∼50% of MDD patients and 10-20% of BPD and Asperger syndrome subjects from controls. These results demonstrate for the first time that a biological signature for SCZ can be identified in blood serum. This study lays the groundwork for development of a diagnostic test that can be used as an aid for distinguishing SCZ subjects from healthy controls and from those affected by related psychiatric illnesses with overlapping symptoms.

AB - Biomarkers are now used in many areas of medicine but are still lacking for psychiatric conditions such as schizophrenia (SCZ). We have used a multiplex molecular profiling approach to measure serum concentrations of 181 proteins and small molecules in 250 first and recent onset SCZ, 35 major depressive disorder (MDD), 32 euthymic bipolar disorder (BPD), 45 Asperger syndrome and 280 control subjects. Preliminary analysis resulted in identification of a signature comprised of 34 analytes in a cohort of closely matched SCZ (n = 71) and control (n = 59) subjects. Partial least squares discriminant analysis using this signature gave a separation of 60-75% of SCZ subjects from controls across five independent cohorts. The same analysis also gave a separation of ∼50% of MDD patients and 10-20% of BPD and Asperger syndrome subjects from controls. These results demonstrate for the first time that a biological signature for SCZ can be identified in blood serum. This study lays the groundwork for development of a diagnostic test that can be used as an aid for distinguishing SCZ subjects from healthy controls and from those affected by related psychiatric illnesses with overlapping symptoms.

KW - biomarkers

KW - bipolar disorder

KW - diagnosis

KW - major depressive disorder

KW - multipleximmunoassay

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84860187759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860187759&partnerID=8YFLogxK

U2 - 10.1038/mp.2011.42

DO - 10.1038/mp.2011.42

M3 - Article

VL - 17

SP - 494

EP - 502

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 5

ER -